| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
AMRX Stock Overview
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas.
Rewards
Risk Analysis
No risks detected for AMRX from our risk checks.
Amneal Pharmaceuticals Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.00 |
| 52 Week High | US$5.99 |
| 52 Week Low | US$2.88 |
| Beta | 1.21 |
| 1 Month Change | -4.15% |
| 3 Month Change | -13.79% |
| 1 Year Change | -37.11% |
| 3 Year Change | 8.30% |
| 5 Year Change | n/a |
| Change since IPO | -80.01% |
Recent News & Updates
Amneal Pharmaceuticals Q2 2022 Earnings Preview
Amneal Pharmaceuticals (NYSE:AMRX) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is $0.19 (-24.0% Y/Y) and the consensus Revenue Estimate is $534.44M (-0.1% Y/Y). Over the last 2 years, AMRX has beaten EPS estimates 75% of the time and has beaten revenue estimates 63% of the time. Over the last 3 months, EPS estimates have seen 2 upward revisions and 5 downward. Revenue estimates have seen 0 upward revisions and 6 downward.
Shareholder Returns
| AMRX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -2.9% | 0.3% | 4.5% |
| 1Y | -37.1% | -0.9% | -8.9% |
Return vs Industry: AMRX underperformed the US Pharmaceuticals industry which returned 0.3% over the past year.
Return vs Market: AMRX underperformed the US Market which returned -9.6% over the past year.
Price Volatility
| AMRX volatility | |
|---|---|
| AMRX Average Weekly Movement | 8.9% |
| Pharmaceuticals Industry Average Movement | 12.1% |
| Market Average Movement | 7.6% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AMRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: AMRX's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 7,000 | Chirag Patel | https://www.amneal.com |
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
Amneal Pharmaceuticals Fundamentals Summary
| AMRX fundamental statistics | |
|---|---|
| Market Cap | US$939.48m |
| Earnings (TTM) | -US$133.58m |
| Revenue (TTM) | US$2.12b |
0.2x
P/S Ratio-3.4x
P/E RatioIs AMRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMRX income statement (TTM) | |
|---|---|
| Revenue | US$2.12b |
| Cost of Revenue | US$1.36b |
| Gross Profit | US$763.45m |
| Other Expenses | US$897.03m |
| Earnings | -US$133.58m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.88 |
| Gross Margin | 35.97% |
| Net Profit Margin | -6.29% |
| Debt/Equity Ratio | 1,454.5% |
How did AMRX perform over the long term?
See historical performance and comparisonValuation
Is AMRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AMRX?
Other financial metrics that can be useful for relative valuation.
| What is AMRX's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | US$939.48m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.5x |
| Enterprise Value/EBITDA | 7.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does AMRX's PS Ratio compare to its peers?
| AMRX PS Ratio vs Peers |
|---|
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.6x | ||
INVA Innoviva | 2.5x | -41.4% | US$1.0b |
PROC Procaps Group | 2.1x | 11.8% | US$880.0m |
PAHC Phibro Animal Health | 0.8x | 4.1% | US$759.4m |
NKTR Nektar Therapeutics | 9.1x | 7.2% | US$877.1m |
AMRX Amneal Pharmaceuticals | 0.2x | 3.5% | US$939.5m |
Price-To-Sales vs Peers: AMRX is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (3.6x).
Price to Earnings Ratio vs Industry
How does AMRX's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Sales vs Industry: AMRX is good value based on its Price-To-Sales Ratio (0.2x) compared to the US Pharmaceuticals industry average (3.9x)
Price to Sales Ratio vs Fair Ratio
What is AMRX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.2x |
| Fair PS Ratio | 2.2x |
Price-To-Sales vs Fair Ratio: AMRX is good value based on its Price-To-Sales Ratio (0.2x) compared to the estimated Fair Price-To-Sales Ratio (2.2x).
Share Price vs Fair Value
What is the Fair Price of AMRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: AMRX ($3) is trading below our estimate of fair value ($20.42)
Significantly Below Fair Value: AMRX is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Future Growth
How is Amneal Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Future Growth Score
4/6Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
70.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AMRX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: AMRX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AMRX is expected to become profitable in the next 3 years.
Revenue vs Market: AMRX's revenue (3.5% per year) is forecast to grow slower than the US market (7.9% per year).
High Growth Revenue: AMRX's revenue (3.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AMRX's Return on Equity is forecast to be very high in 3 years time (43.9%).
Discover growth companies
Past Performance
How has Amneal Pharmaceuticals performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-25.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AMRX is currently unprofitable.
Growing Profit Margin: AMRX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AMRX is unprofitable, and losses have increased over the past 5 years at a rate of 25.6% per year.
Accelerating Growth: Unable to compare AMRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AMRX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.5%).
Return on Equity
High ROE: AMRX has a negative Return on Equity (-143.07%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is Amneal Pharmaceuticals's financial position?
Financial Health Score
4/6Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: AMRX's short term assets ($1.6B) exceed its short term liabilities ($993.1M).
Long Term Liabilities: AMRX's short term assets ($1.6B) do not cover its long term liabilities ($2.9B).
Debt to Equity History and Analysis
Debt Level: AMRX's net debt to equity ratio (1405.4%) is considered high.
Reducing Debt: AMRX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable AMRX has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: AMRX is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 28.2% per year.
Discover healthy companies
Dividend
What is Amneal Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AMRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AMRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AMRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AMRX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: AMRX is not paying a notable dividend for the US market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as AMRX has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
4.0yrs
Average management tenure
CEO
Chirag Patel (55 yo)
17.58yrs
Tenure
US$4,785,116
Compensation
Mr. Chirag K. Patel has been Co-Chief Executive Officer, President and Director of Amneal Pharmaceuticals, Inc. since August 3, 2019. Mr. Patel Co-founded Amneal Pharmaceuticals LLC in 2005 and serves as D...
CEO Compensation Analysis
Compensation vs Market: Chirag's total compensation ($USD4.79M) is about average for companies of similar size in the US market ($USD3.83M).
Compensation vs Earnings: Chirag's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: AMRX's management team is considered experienced (4 years average tenure).
Board Members
Experienced Board: AMRX's board of directors are considered experienced (4.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Amneal Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Amneal Pharmaceuticals, Inc.
- Ticker: AMRX
- Exchange: NYSE
- Founded: 2002
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$939.478m
- Market Cap: US$454.226m
- Shares outstanding: 303.53m
- Website: https://www.amneal.com
Number of Employees
Location
- Amneal Pharmaceuticals, Inc.
- 400 Crossing Boulevard
- 3rd Floor
- Bridgewater
- New Jersey
- 8807
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/08/16 00:00 |
| End of Day Share Price | 2022/08/16 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.